Moderna Collaborates with OpenAI to Enhance mRNA Medicines Using Advanced AI

Moderna, Inc., a leader in mRNA technology, has joined forces with AI innovator OpenAI to integrate advanced AI tools across its business operations, announced on April 24, 2024. The collaboration, initiated in early 2023, focuses on leveraging OpenAI's generative AI capabilities to enhance Moderna's drug development processes including vaccine dose optimization through Moderna's internally developed mChat and ChatGPT Enterprise tools.

With the rapid adoption of AI technologies, over 750 GPTs are now operational within Moderna, assisting in areas from legal to manufacturing, augmenting employee capabilities, and optimizing operational efficiency. The collaboration aims to transform the landscape of healthcare and business, echoing the sentiments of Moderna's CEO Stéphane Bancel and OpenAI's CEO Sam Altman, who both highlight the instrumental role of AI in driving transformation and addressing complex problems within healthcare.